|
Rheumatology
Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease
Kyung-Ann Lee, Bo Young Kim, Sung Soo Kim, Yun Hong Cheon, Sang-Il Lee, Sang-Hyon Kim, Jae Hyun Jung, Geun-Tae Kim, Jin-Wuk Hur, Myeung-Su Lee, Yun Sung Kim, Seung-Jae Hong, Suyeon Park, Hyun-Sook Kim
Korean J Intern Med. 2024;39(5):855-864. Published online August 30, 2024
Background/Aims: To compare the effects of abatacept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the progression and development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Methods: This multi-center retrospective study included RA pati..
|
|
|
Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
Bong-Woo Lee, Jennifer Jooha Lee, Wan-Uk Kim
Korean J Intern Med. 2024;39(5):833-844. Published online May 27, 2024
Background/Aims: The aim of this study was to compare the short- and long-term retention rates of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in Korean patients with seropositive rheumatoid arthritis.
Methods: This study was conducted with 1,538 treatment cou..
|
|
|
Effectiveness of Korean Red Ginseng on fatigue in patients with rheumatic diseases: a randomized, double-blind, placebo-controlled study
Soo-Kyung Cho, Yeo-Jin Song, Jung-Yong Han, Hye Won Kim, Eunwoo Nam, Yoon-Kyoung Sung
Korean J Intern Med. 2024;39(4):680-690. Published online April 5, 2024
Background: To evaluate the effectiveness of Korean Red Ginseng (KRG) in managing fatigue in Korean patients with rheumatic diseases
Methods: Patients were randomly assigned to KRG (2 g/day, n = 60) or placebo (n = 60) groups for 12 weeks of blind phase and then open-label KRG from weeks 12 to 24 (..
|
|
|
Impact of socioeconomic status on biologics utilization in rheumatoid arthritis: revealing inequalities and healthcare efficiency
Hye Won Kim, Yeon Ju Lee, You-Jung Ha, Eun Bong Lee, Yun Jong Lee, Eun Ha Kang
Korean J Intern Med. 2024;39(4):668-679. Published online February 29, 2024
Background/Aims: This cross-sectional study aimed to investigate biologics treatment disparities in rheumatoid arthritis (RA) patients based on socioeconomic status (SES).
Methods: Data from the KOrean Observational Study Network for Arthritis (KORONA) database were analyzed to assess various facto..
|
|
|
Clinical characteristics and prognostic factors of non-tuberculous mycobacterial disease in patients with rheumatoid arthritis
Hyemin Kim, Soyoung Lee, Ji-Won Kim, Ju-Yang Jung, Chang-Hee Suh, Hyoun-Ah Kim
Korean J Intern Med. 2024;39(1):172-183. Published online November 30, 2023
Background/Aims: This study aimed to identify the clinical characteristics of patients with concurrent rheumatoid arthritis (RA) and suspected non-tuberculous mycobacterial (NTM) infections as well as determine their prognostic factors.
Methods: We retrospectively reviewed the medical records of 91..
|
|
|
Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab
Mie Jin Lim, Kyong-Hee Jung, Seong-Ryul Kwon, Won Park
Korean J Intern Med. 2023;38(6):912-922. Published online October 23, 2023
Background/Aims: We investigated the effect of rituximab on systemic bone metabolism in patients with seropositive rheumatoid arthritis (RA).
Methods: Twenty seropositive patients with RA were enrolled and administered one cycle of rituximab. If RA became active for > 6 months after the first ritux..
|
|
|
Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Soo-Kyung Cho, Hyoungyoung Kim, Yeo-Jin Song, Hye Won Kim, Eunwoo Nam, Shin-Seok Lee, Hye-Soon Lee, Sung-Hoon Park, Yeon-Ah Lee, Min-Chan Park, Sung Hae Chang, Hyoun-Ah Kim, Seung-Ki Kwok, Hae-Rim Kim, Hyun-Sook Kim, Bo Young Yoon, Wan-Sik Uhm, Yong-Gil Kim, Jae Hoon Kim, Jisoo Lee, Jeongim Choi, Yoon-Kyoung Sung
Korean J Intern Med. 2023;38(4):546-556. Published online June 20, 2023
Background/Aims: We aimed to compare the effectiveness and safety of Janus kinase inhibitors (JAKi) vs. biologic disease- modifying antirheumatic drugs (bDMARD) in Korean patients with rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic DMARDs.
Methods: A quasi-exper..
|
|
|
Incidence and prevalence of seropositive rheumatoid arthritis among Korean women of childbearing age: a nationwide population-based study
Min Kyung Chung, Chan Hee Lee, Jin Su Park, Hyun Sun Lim, Jisoo Lee
Korean J Intern Med. 2023;38(1):125-133. Published online May 19, 2022
Background/Aims: Women with rheumatoid arthritis (RA) are often diagnosed with the disease during their reproductive years; however, its incidence and prevalence among women of childbearing age have not been studied. The objective of this study was to estimate the incidence and prevalence of seropos..
|
|
|
Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea
Kyung Min Ko, Su-Jin Moon
Korean J Intern Med. 2023;38(1):113-124. Published online August 20, 2021
Background/Aims: This study aims to evaluate the incidence of malignancy in patients with rheumatoid arthritis (RA) and to investigate risk factors for such in a nationwide, population-based cohort.
Methods: In a large, prospective, observational cohort study, 5,077 patients with RA were enrolled f..
|
|
|
Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
Kichul Shin, Hyun Mi Kwon, Min Jung Kim, Myung Jae Yoon, Hyun Gyung Chai, Seong-Wook Kang, Won Park, Sung-Hwan Park, Chang Hee Suh, Hyun Ah Kim, Seung-Geun Lee, Choong Ki Lee, Sang-Cheol Bae, Yong-Beom Park, Yeong Wook Song
Korean J Intern Med. 2022;37(5):1061-1069. Published online December 13, 2021
Background/Aims: The aim of this study was to investigate long-term post-discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-α inhibitors (TNF-αi) which was then discontinued.
Methods: Sixty Korean patients with RA who participated i..
|
|
|
Perioperative and anesthetic management of patients with rheumatoid arthritis
Hae-Rim Kim, Seong-Hyop Kim
Korean J Intern Med. 2022;37(4):732-739. Published online June 3, 2022
Our understanding and management of rheumatoid arthritis (RA) have greatly improved, but perioperative and anesthetic management remain challenging. RA is not limited to joints; systemic evaluation is thus required when planning perioperative management. Especially, careful airway evaluation is need..
|
|
|
Rheumatology
Trends in hospital visits and healthcare costs of gout and seropositive rheumatoid arthritis in Korea from 2010 to 2017 using National Healthcare Claims
Kyeong Min Son, Ju-Ryoung Kim, Hang A Park, Hyun Ah Kim
Korean J Intern Med. 2022;37(3):681-690. Published online October 26, 2021
Background/Aims: We examined temporal trends in the rate of gout and seropositive rheumatoid arthritis (RA) hospital visits and healthcare costs in Korea.
Methods: We conducted a serial cross-sectional analysis of Korean national healthcare claims. We calculated the annual increase in hospital visi..
|
|
|
Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease
Ji-Won Kim, Jung-Yoon Choe, Sung-Hwan Park
Korean J Intern Med. 2022;37(1):13-26. Published online December 10, 2021
Metformin is a first-line therapeutic agent for type 2 diabetes. Apart from its glucose- lowering effect, metformin is attracting interest regarding possible therapeutic benefits in various other conditions. As metformin regulates cell metabolism, proliferation, growth, and autophagy, it may also mo..
|
|
|
Rheumatology
Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis
Kyoung-Woon Kim, Bo-Mi Kim, Ji-Yeon Won, Hong Ki Min, Seoung Joon Lee, Sang-Heon Lee, Hae-Rim Kim
Korean J Intern Med. 2021;36(Suppl 1):S273-S282. Published online June 19, 2020
Background/Aims: The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA).
Methods: We evaluated the effect of tocotrienol on IL-17-induced receptor activator of nuclear factor kappa B ligand (RANKL) producti..
|
|
|
Predictors of joint damage in patients with rheumatoid arthritis: focus on short- and long-term effects of intra-articular glucocorticoid injections
Jung Hee Koh, Hanna Lee, Seung-Geun Lee
Korean J Intern Med. 2021;36(6):1515-1526. Published online February 15, 2021
Background/Aims: To investigate the short- and long-term efficacy of intra-articular glucocorticoid injections (IAGI) in patients with rheumatoid arthritis (RA).
Methods: This was a retrospective study of RA patients who had active arthritis in the hand or wrist joints and who received IAGI (or not..
|
|
|
Developing the Korean Educational Needs Assessment Tool (Korean ENAT) in rheumatoid arthritis: cross-cultural validation using Rasch analysis
Yoon-Kyoung Sung, Hyoungyoung Kim, Sung Joo Cha, Sae-Hyung Kim, Mwidimi Ndosi, Soo-Kyung Cho
Korean J Intern Med. 2021;36(4):1014-1022. Published online October 30, 2020
Background/Aims: This study was performed to undertake cross-cultural adaptation and validation of the Educational Needs Assessment Tool (ENAT) in rheumatoid arthritis (RA) for use in Korea.
Methods: The study involved two main phases: cross-cultural adaptation of the ENAT from English into Korean,..
|
|
|
Association of body composition with disease activity and disability in rheumatoid arthritis
Kyeong Min Son, Seong Hun Kang, Young Il Seo, Hyun Ah Kim
Korean J Intern Med. 2021;36(1):214-222. Published online May 15, 2020
Background/Aims: To explore the associations between body composition and pain, disease activity, and disability in rheumatoid arthritis (RA).
Methods: The study enrolled 335 patients with RA and underwent body composition measurement with an InBody analyzer. The associations of body mass index (BM..
|
|
|
Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis
Bon San Koo, Sungsin Jo, Eunji Kwon, Ji Hui Shin, Jin-Wuk Hur, Tae-Hwan Kim
Korean J Intern Med. 2020;35(2):465-473. Published online December 16, 2019
Background/Aims: Biologics are very effective drugs for patients with ankylosing spondylitis (AS). However, there are patients who are not responding to biologics. This study aimed to evaluate the level of tumor necrosis factor α (TNF-α), interleukin (IL)-23, and IL-17 from synovial fluid in patie..
|
|
|
Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity
Kichul Shin, Sung Soo Kim, Sang-Heon Lee, Seung-Jae Hong, Sung Jae Choi, Jung-Yoon Choe, Seung-Geun Lee, Hoon-Suk Cha, Eun Young Lee, Sung-Hwan Park, Jin-Wuk Hur, Sung Soo Na, Chang-Hee Suh, Min Wook So, Seung Won Choi, Dong-Hyuk Sheen, Won Park, Shin-Seok Lee, Wan Hee Ryu, Jin Seok Kim, Jung Soo Song, Hye Soon Lee, Seong Ho Kim, Dae-Hyun Yoo
Korean J Intern Med. 2020;35(1):231-239. Published online January 28, 2019
Background/Aims: The objective of this study was to compare changes in the simplified disease activity index (SDAI) between biologic (b) and conventional (c) disease-modifying antirheumatic drugs (DMARD) users with seropositive rheumatoid arthritis (RA) in daily clinical practice. Methods: This was ..
|
|
|
The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
Korean J Intern Med. 2020;35(1):41-59. Published online January 2, 2020
Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inf lammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bDMARDs market in Korea, reports of serious adverse events ..
|
|
|
